Qualigen Therapeutics’ Striking Pivot: From Biotech to Blockchain
Shares of Qualigen Therapeutics (QLGN) surged nearly 200% on Monday following news of a substantial $41 million investment from Faraday Future (FFAI) and its founder YT Jia. This strategic investment has ignited excitement among investors, largely due to the company’s rebranding as CXC10 and its ambitious shift towards the cryptocurrency and Web3 sectors.
The newly rebranded CXC10 introduced three primary growth initiatives: a crypto treasury, an AI-driven trading platform dubbed DeAI, and the development of ecosystem tokens. Each of these components has the potential to reshape the company’s market presence and attract a new audience.
Following the announcement, QLGN shares have experienced a reversal, but remain up approximately 190% from their year-to-date lows at the time of writing.
The acquisition of a majority stake by FFAI has bolstered investor confidence in Qualigen, showcasing a clear commitment rather than mere interest. With Faraday securing 55% ownership and Jia an additional 7% under a two-year lockup agreement, this partnership lends serious credibility and support to CXC10’s endeavors.
Moreover, the transition into the crypto and Web3 arena introduces a layer of speculative excitement surrounding early successes from the C10 treasury and the anticipated capabilities of AI-based trading through their BesTrade platform.
This narrative may appear enticing to retail investors as it combines electric vehicle technology, decentralized AI, and token economies. However, this steep departure from Qualigen’s traditional biotech roots raises valid concerns regarding implementation and the sustainability of the new strategies.
Despite the enthusiasm surrounding the rebranding, Qualigen’s financial outlook remains worrisome for the second half of 2025. The company struggles with a history of losses, minimal revenue streams, and a fragile balance sheet that raises concerns about potential dilution of shareholder value. Additionally, its biotech legacy does not align cohesively with its new Web3 aspirations, presenting a challenge to its strategic realignment.
Establishing a solid valuation remains difficult, particularly given that there is no proven product-market fit in the crypto space as of now. The reported 7% gain on its treasury does little to eliminate caution surrounding its overall viability.
In conclusion, with the looming threats of regulatory challenges, execution risks, and speculative bubbles, QLGN stock represents a high-risk investment. Long-term investors may be prudent to wait for substantive progress before committing, especially given that Qualigen Therapeutics currently lacks coverage from Wall Street analysts.
On the date of publication, Wajeeh Khan did not hold any positions in the securities discussed in this article. All information and data within this article are for informational purposes only. Originally published on Barchart.com.
